UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME

ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, August 11, 2022

Information

Tags:

Twitter, SAN, Biotechnology, Unity Biotechnology, UCSF, Therapy, Nasdaq, Ageing, LinkedIn, UBX, GLOBE, Lists of diseases, UNITY, Pharmaceutical industry, Ophthalmology

Geotags:

SOUTH SAN FRANCISCO, CA, US

Organisation:

UNITY BIOTECHNOLOGY, INC.

Summary

Key Points:

ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.
The live webcast can be accessed in the Investors and Media section of our website, www.unitybiotechnology.com , under Events & Presentations or by clicking here .
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging.
UNITYs current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an investor call to discuss lead program, UBX1325 on Friday, August 12, 2022 at 5:00 a.m. ET/8:00 a.m. ET, with retinal expert Robert Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, UCSF.

The live webcast can be accessed in the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations” or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, under “Events and Presentations.”

About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact:
Evoke Canale
Katherine Smith
[email protected]

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
[email protected]

Source: Unity Biotechnology, Inc